- Details
- Pedro Barata converses with Neil Shah about his research on clinical outcomes for patients with advanced RCC. They focus on two of Dr. Shah's studies: 'Real-World Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab’, and ‘Real-World Assessment of Changing Treatment Patterns and Sequence for Patients with Metastatic RCC in...
|
- Details
- Alicia Morgans interviews Herb Geller about a study into peer-led support groups for prostate cancer patients. Dr. Geller explains the AnCan model which is focused on online peer-led support groups catering to different types of prostate cancer. These groups provide a platform for patients to share their experiences, ask questions, and gain information without additional irrelevant data. As a part...
|
- Details
- Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr. Sternbe...
|
- Details
- Chadi Nabhan joins Charles Ryan to discuss The Caris Precision Oncology Alliance™ (POA), which focuses on precision oncology to optimize clinical care and outcomes of patients with cancer. The Precision Oncology Alliance gathers real-world data from patients that undergo molecular tumor profiling across the spectrum of solid malignancies and feeds the data into a large database that can be accesse...
|
- Details
- Joining Charles Ryan is Emmanuel Antonarakis to detail the present state of bipolar androgen therapy (BAT) and where the field going. Biographies: Emmanuel Antonarakis, MD, Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Charles J. Ryan, MD , the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the wor...
|
- Details
- Oliver Sartor is joined by Alicia Morgans to discuss her presentation at the GU ASCO 2022 Annual Meeting on the largest digital survey conducted in patients with prostate cancer, the initial results of an international survey of patients with prostate cancer. The goal of this survey was to map patient experiences, expectations, and attitudes, and to identify challenges and unmet needs in diagnosis...
|
- Details
- Tanya Dorff joins Alicia Morgans to discuss the highlights from her presentation at the 2022 GU ASCO Annual meeting focusing on new targets in prostate cancer beyond prostate-specific membrane antigen (PSMA). She highlights potential new targets including prostate stem cell antigen (PSCA), JNJ-75229414 is a KLK2 CAR T, and STEAP-1. Drs. Morgans and Dorff also discuss tumor heterogeneity and neuroe...
|
- Details
- Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal's discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the Depa...
|
- Details
- Hielke Martijn de Vries joins Alicia Morgans to discuss immunotherapy with or without radiation therapy for advanced penile cancer patients, the results of the PERICLES study. PERICLES is a phase II trial investigating atezolizumab +/- radiotherapy for advanced squamous cell carcinoma of the penis. Biographies: Hielke Martijn de Vries, Department of Urology, Netherlands Cancer Institute, Amsterdam...
|
- Details
- Petros Grivas is joined by Dimitrios Makrakis to discuss his multi-institutional retrospective cohort study of patients with advanced urothelial carcinoma (UC) who received platinum-based chemotherapy in the first line, followed by second-line immune checkpoint inhibitor (ICI). In this study, the timely question of how the duration of response to immune checkpoint inhibitor may be interpreted as p...
|
